Latest News

Geographic determinants of health: location, location

 

Geography has a significant impact on MS patients’ access to care and treatment options, according to data presented at the Consortium of MS Centers (CMSC) 38th annual meeting, held May 29-June 1 in Nashville, Tennessee. Read More

TOPICS:

New guidance on use of sNfL in practice

 

An international panel of experts in conjunction with the Consortium of MS Centers (CMSC) has developed recommendations on the use of neurofilament-light chain (NfL) as a biomarker of disease activity in multiple sclerosis (Freedman et al. eBioMedicine 2024;101:104970). Read More

New developments in epilepsy: focus on cenobamate

 

Cenobamate received Health Canada authorization last year as adjunctive therapy for patients with partial-onset seizures who are not adequately controlled with conventional therapies. The drug acts as a sodium channel blocker through selection inhibition of the persistent sodium current, and as a GABAA receptor modulator. Read More

Treatment initiation with a higher-efficacy DMT: update from AAN

 

Focus on ofatumumab

There is a growing body of evidence supporting the use of high-efficacy disease-modifying therapies (DMT) as first-line agents in the treatment of multiple sclerosis. Since the TRANSFORMS trial over a decade ago, numerous pivotal trials have demonstrated the superiority of higher-efficacy DMTs over lower-efficacy agents (Cohen et al. N Engl J Med 2010;362:402-415). The concern with this more aggressive approach was safety. However, the accumulation of long-term safety data, most notably for anti-CD20 agents, has demonstrated the low risk of serious adverse events with sustained exposure to selected high-efficacy DMTs in clinical practice. Read More